A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab

Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecan-induced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Tsung-Kun, Yin, Tzu-Chieh, Su, Wei-Chih, Tsai, Hsiang-Lin, Huang, Ching-Wen, Chen, Yen-Cheng, Li, Ching-Chun, Chen, Po-Jung, Ma, Cheng-Jen, Chuang, Kuo-Hsiang, Cheng, Tian-Lu, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420909/
https://www.ncbi.nlm.nih.gov/pubmed/34030768
http://dx.doi.org/10.3727/096504021X16218531628569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420909/
https://www.ncbi.nlm.nih.gov/pubmed/34030768
http://dx.doi.org/10.3727/096504021X16218531628569

Ejemplares similares